BDTX
Black Diamond Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$151.85M
P/E Ratio
6.79
EPS
$0.39
Beta
3.39
52W High
$4.94
52W Low
$1.46
50-Day MA
$2.46
200-Day MA
$2.95
Dividend Yield
—
Profit Margin
32.00%
Forward P/E
8.33
PEG Ratio
—
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $70.00M |
| Gross Profit (TTM) | $70.00M |
| EBITDA | $20.20M |
| Operating Margin | 28.40% |
| Return on Equity | 22.90% |
| Return on Assets | 9.35% |
| Revenue/Share (TTM) | $1.23 |
| Book Value | $1.96 |
| Price-to-Book | 1.35 |
| Price-to-Sales (TTM) | 2.17 |
| EV/Revenue | 0.6 |
| EV/EBITDA | 2.08 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $57.30M |
| Float | $46.25M |
| % Insiders | 0.62% |
| % Institutions | 77.38% |
Historical Volatility
HV 10-Day
81.53%
HV 20-Day
71.59%
HV 30-Day
67.82%
HV 60-Day
73.82%
HV Rank
29.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($9.86 target)
2
Strong Buy6
Buy1
HoldData last updated: 5/1/2026